Skip to content
Events
webinar image

Details

The MiSeq i100 Series is the latest benchtop sequencer from Illumina. It delivers breakthrough simplicity, our fastest run times yet, comprehensive analysis, and significant sustainability advancements. In this webinar, you will: 

  • Uncover the power of the MiSeq i100 Series and its breakthrough innovations
  • Explore cutting-edge application data in oncology, microbiology, and infectious disease 
  • Gain insights from early-access users and their experiences with the platform 
Jacob Thaysen

Jacob Thaysen, PhD
Chief Executive Officer
Illumina

Everett Cunningham

Everett Cunningham
Chief Commercial Officer
Illumina

Emmanuel Naouri

Emmanuel Naouri
Associate Director, Product Management
Illumina

Steve Barnard

Steve Barnard, PhD
Chief Technology Officer
Illumina

Dr. Ali Crawford

Ali Crawford, PhD
Sr Director, Scientific Research
Illumina

This webinar is presented in English. Optional subtitles are available in select languages, including English, French, Italian, Spanish, Portuguese, Chinese, Japanese, and Korean.

Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
9 Oct. 2024
09:00 AM
Time zone: PT
Presenter
Jacob Thaysen, PhD
Everett Cunningham
Emmanuel Naouri
Steve Barnard, PhD
Ali Crawford, PhD
Early-access users
Topic
Cancer research, Cellular & molecular biology, Microbial genomics, Oncology, Instruments
Watch Now

Related Events

Nov 5
ASHG Annual Meeting 2024
Nov 5, 2024 – Nov 9, 2024
Visit Illumina booth 503 at ASHG 2024, and attend our colab and sessions to hear more about our products, solutions, and partnerships.
View Event
Nov 6
Your Vision Our Workflow - Illumina’s solution for clinical research in rare and inherited disease
Nov 6, 2024
In this webinar you will hear from two speakers: Anthony Beckhouse on the benefits and flexibility of the NextSeq 1K/2k, and Michael Fietz on the accuracy and speed of our secondary analysis solution DRAGEN, as well as how our tertiary analysis solution Emedgene can help address bottlenecks of analysis and reporting for rare and inherited disease research. With Illumina’s exome or genome sequencing as a backbone, and the ability to do virtual panels with our tertiary solution - Emedgene. Laboratories can now create comprehensive assays to enable the latest genomic discoveries.
View Event
Nov 6
Your Vision Our Workflow - Illumina’s solution for clinical research in rare and inherited disease
Nov 6, 2024
In this webinar you will hear from two speakers: Anthony Beckhouse on the benefits and flexibility of the NextSeq 1K/2k, and Michael Fietz on the accuracy and speed of our secondary analysis solution DRAGEN, as well as how our tertiary analysis solution Emedgene can help address bottlenecks of analysis and reporting for rare and inherited disease research. With Illumina’s exome or genome sequencing as a backbone, and the ability to do virtual panels with our tertiary solution - Emedgene. Laboratories can now create comprehensive assays to enable the latest genomic discoveries.
View Event
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.